WHO WE ARE

Aprea Therapeutics is a Boston, Massachusetts and Stockholm, Sweden based biopharmaceutical company focused on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The Company’s lead drug candidate is APR-246, a small molecule in clinical development for myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies, and we believe APR-246 will be a first-in-class therapy if approved by applicable regulators.  Aprea has commenced a Phase 3 clinical study in p53 mutated MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutated high-risk MDS and AML with APR-246 and azacitidine. Additional Phase 1b/2 studies for APR-246 in MDS and AML are also underway and in planning together with other approved anti-cancer agents.  Aprea is also developing second generation p53 reactivators. The Company recently completed a Series C financing raising a total of approximately US$62 million.  The financing round was led by the Redmile Group, with participation by Rock Springs Capital and Janus Henderson Investors, and included existing investors: 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB (Nasdaq Stockholm: KDEV).

Explore Partnership Opportunities

3box_1APR-246

Strong synergy with other anticancer drugs

Learn More

cad_greenp53

Tumor suppressor and key to cancer treatment

Learn More

news_blueLatest News

FDA grants Fast Track and Orphan Drug Designations to APR-246

Learn More

PARTNERING

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Nullam dictum felis eu pede mollis pretium. Integer tincidunt.

Get Investor Information